BioVie Inc. (BIVI)
NASDAQ: BIVI · Real-Time Price · USD
1.250
-0.010 (-0.79%)
At close: Feb 23, 2026, 4:00 PM EST
1.280
+0.030 (2.40%)
Pre-market: Feb 24, 2026, 8:44 AM EST
BioVie Employees
BioVie had 13 employees as of June 30, 2025. The number of employees decreased by 1 or -7.14% compared to the previous year.
Employees
13
Change (1Y)
-1
Growth (1Y)
-7.14%
Revenue / Employee
n/a
Profits / Employee
-$1,344,472
Market Cap
9.43M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 13 | -1 | -7.14% | 13 | 0 |
| Jun 30, 2024 | 14 | -4 | -22.22% | 14 | 0 |
| Jun 30, 2023 | 18 | 5 | 38.46% | 18 | 0 |
| Jun 30, 2022 | 13 | 7 | 116.67% | 13 | 0 |
| Jun 30, 2021 | 6 | 2 | 50.00% | 6 | 0 |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 57 |
| Bolt Biotherapeutics | 40 |
| KALA BIO | 38 |
| NuCana | 22 |
| SeaStar Medical Holding | 19 |
| Akari Therapeutics, | 9 |
| TransCode Therapeutics | 7 |
| Pulmatrix | 2 |
BIVI News
- 11 days ago - Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewsWire
- 2 months ago - HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PRNewsWire
- 2 months ago - BioVie Inc. (BIVI) Discusses Clinical Progress of Lead Drug Candidates Targeting Parkinson's, Alzheimer's, and Liver Disease Transcript - Seeking Alpha
- 3 months ago - Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9 - GlobeNewsWire
- 4 months ago - BioVie Inc. - Special Call - Seeking Alpha
- 5 months ago - BioVie to Host Live Investor Webinar and Q&A on Oct. 8 - GlobeNewsWire
- 6 months ago - BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes - GlobeNewsWire
- 7 months ago - BioVie Inc. Announces Pricing of $12 Million Public Offering - GlobeNewsWire